Please note that this product was withdrawn from the Community register of designated orphan medicinal products in July 2013 on request of the sponsor.
On 24 July 2009, orphan designation (EU/3/09/658) was granted by the European Commission to Eudax S.R.L., Italy, for tamibarotene for the treatment of acute promyelocytic leukaemia.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
|Disease / condition||
Treatment of acute promyelocytic leukaemia
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.